| 2—1 |
CF coating slurry formulation |
7
|
| 3—1 |
Exposures from CCP handling |
14
|
| 3—2 |
Solvent emissions from CCP with intact microcapsules and 1% crushed microcapsules (mg/m2 per hour) |
17
|
| 3—3 |
Airborne concentrations of total dust and solvents produced with standardized paper handling in the laboratory (mg/m3) |
18
|
| 3—4 |
GC/MS analysis of CCP samples, SurSol 290 solvent, and area air samples (ppb) |
20
|
| 3—5 |
Formaldehyde concentration after repeated turning of CCP sheets in a test chamber |
22
|
| 3—6 |
Formaldehyde concentrations in the test chamber at various points after turning (total of 60 sheets for each condition) |
23
|
| 3—7 |
Formaldehyde concentrations in the test chamber during a 90-min period |
23
|
| 3—8 |
Formaldehyde concentrations in a test chamber containing eight CCP products |
24
|
| 3—9 |
Effect of ventilation on formaldehyde concentrations in test chambers containing CCP |
26
|
| 3—10 |
Summary of formaldehyde concentrations reported in CCP studies |
26
|
| 4—1 |
Published case reports, case series, and health hazard evaluations involving exposure to CCP or CCP components |
31
|
| 4—2 |
Summary of health-related inquiries from customers to Appleton Papers, Inc., May 1976 to December 1986 |
47
|
| 4—3 |
Summary of cross-sectional studies that used questionnaires to assess the health effects of indoor air contaminants in general or CCP specifically |
49
|
| 4—4 |
Job or workspace factors associated with the prevalence of work-related symptoms after adjustment for other personal, psychological, job, workspace, and building factors in northern California office workers, June—September 1990
|
59
|
| 4—5 |
Types and locations of skin and mucous membrane symptoms in a Swedish questionnaire study |
62
|
| 4—6 |
Dose-response relationship of CCP handling frequency with symptoms reported by respondents |
64
|
| 4—7 |
Frequency of respiratory tract symptoms by type of paper and exposure level |
65
|
| 4—8 |
Positive findings from physician interviews of 53 respondents to a health questionnaire |
67
|
| 4—9 |
Dose-response relationship between CCP handling and mucous membrane and skin symptoms in two form-printing shops |
68
|
| 4—10 |
Incidence of symptoms in exposed workers and their matched comparison workers during two exposure periods |
69
|
| 4—11 |
Experimental laboratory investigations of allergic and irritative reactions in humans exposed to CCP |
72
|
| 4—12 |
Analysis of repeated insult patch test (RIPT) studies submitted by industry clients in response to 1987 and 1997 Federal Register notices on CCP and its components |
76
|
| 4—13 |
Frequency of occurrence and animal irritation category for chemicals identified in 12 French CCPs |
100
|
| 5—1 |
Summary of studies that examined exposure-response relationships between CCP handling and irritative symptoms of the skin, eyes, or upper respiratory tract |
108
|
| 5—2 |
Elevated ORs for CCP exposure and irritation of the skin, eyes, nose, or respiratory system reported in the indoor air cross-sectional studies |
109
|
